Developing novel anti-infective drugs is essential to combat antimicrobial resistance,address emerging pathogens,and safeguard global health against evolving infectious threats.A recent publication in the esteemed jou...Developing novel anti-infective drugs is essential to combat antimicrobial resistance,address emerging pathogens,and safeguard global health against evolving infectious threats.A recent publication in the esteemed journal Nature by Qisen Deng et al.reported on the comprehensive evaluation of the therapeutic efficacy of mandimycin against multidrug-resistant(MDR)fungal pathogens.The polyene macrolide antifungal antibiotic,mandimycin,was discovered using a phylogeny-guided natural-product discovery platform.Authors utilized various in vivo mouse models such as systemic and soft-tissue infections to assess the antifungal activity of mandimycin.The efficacy was measured by quantifying the fungal burden in major organs and assessing survival rates.In systemic infections,mandimycin demonstrated significant dose-dependent antifungal efficacy,as compared to amphotericin B,particularly in cases where the latter was ineffective against MDR C.auris.Furthermore,mandimycin showed a favorable safety profile,with low toxicity and no observed side effects at effective doses.The study's findings contribute valuable insights into the potential of mandimycin as a novel antifungal agent,offering hope for improved treatment options against challenging fungal infections.The results pave the way for further research and clinical applications in the fight against antifungal resistance.展开更多
The efficacy of conventional antibiotics against multidrug-resistant pathogenic fungi is markedly limited.A study published in Nature by Wang et al.introduced mandimycin,a novel antifungal agent with a distinct mechan...The efficacy of conventional antibiotics against multidrug-resistant pathogenic fungi is markedly limited.A study published in Nature by Wang et al.introduced mandimycin,a novel antifungal agent with a distinct mechanism of action,diverging from established polyene macrolide antibiotics that target ergosterol.The emergence of multidrug-resistant fungal pathogens poses substantial risks to patient health,healthcare infrastructures,and public health at large.The alarming increase in these pathogens is attributed to their capability to withstand numerous antifungal treatments,resulting in escalated morbidity and mortality rates among affected patients.The strategies employed by these pathogens to compromise patient health include modifications at drug target sites,improved efflux mechanisms,and biofilm formation,all of which complicate treatment protocols and extend hospital stays[1].This concerning trend accentuates the urgent need for ongoing monitoring and investigation into innovative antifungal agents and therapeutic approaches to address these resilient pathogens.展开更多
基金the National Key Research and Development Program of China(2023YFD1700500)the College Student Research Training Program(202110307002T)Bayer Grants4Ag Initiative for their support.
文摘Developing novel anti-infective drugs is essential to combat antimicrobial resistance,address emerging pathogens,and safeguard global health against evolving infectious threats.A recent publication in the esteemed journal Nature by Qisen Deng et al.reported on the comprehensive evaluation of the therapeutic efficacy of mandimycin against multidrug-resistant(MDR)fungal pathogens.The polyene macrolide antifungal antibiotic,mandimycin,was discovered using a phylogeny-guided natural-product discovery platform.Authors utilized various in vivo mouse models such as systemic and soft-tissue infections to assess the antifungal activity of mandimycin.The efficacy was measured by quantifying the fungal burden in major organs and assessing survival rates.In systemic infections,mandimycin demonstrated significant dose-dependent antifungal efficacy,as compared to amphotericin B,particularly in cases where the latter was ineffective against MDR C.auris.Furthermore,mandimycin showed a favorable safety profile,with low toxicity and no observed side effects at effective doses.The study's findings contribute valuable insights into the potential of mandimycin as a novel antifungal agent,offering hope for improved treatment options against challenging fungal infections.The results pave the way for further research and clinical applications in the fight against antifungal resistance.
基金supported by the National Natural Science Foundation of China(82460111)the The First People’s Hospital of Yunnan Province Talent Project program(No.KHBS-2022013,KHYJ-2025-04-02,2022-KHRCBZ-B03)+4 种基金the Kunming Medical University Joint Special Project on Applied Basic Research(202301AY070001-210)Yunnan Provincial Key Laboratory of Clinical Virology(No.2023A4010403-04)Yunnan Foundmental basical research project(202301AT070034)the Yunnan Provincial Key Laboratory of Birth Defects and Genetic Diseases(No.2022ZDKFKT001)the Open Project of Yunnan Provincial Clinical Medical Research Center for Elderly Diseases(No.:2023YJZX-LN03/13 of 202102AA3100692023).
文摘The efficacy of conventional antibiotics against multidrug-resistant pathogenic fungi is markedly limited.A study published in Nature by Wang et al.introduced mandimycin,a novel antifungal agent with a distinct mechanism of action,diverging from established polyene macrolide antibiotics that target ergosterol.The emergence of multidrug-resistant fungal pathogens poses substantial risks to patient health,healthcare infrastructures,and public health at large.The alarming increase in these pathogens is attributed to their capability to withstand numerous antifungal treatments,resulting in escalated morbidity and mortality rates among affected patients.The strategies employed by these pathogens to compromise patient health include modifications at drug target sites,improved efflux mechanisms,and biofilm formation,all of which complicate treatment protocols and extend hospital stays[1].This concerning trend accentuates the urgent need for ongoing monitoring and investigation into innovative antifungal agents and therapeutic approaches to address these resilient pathogens.
